Boston Scientific Completes Major Acquisition in Urology Technology

Axonics Modulation US05465P1012

The landscape of the medical device sector has shifted with the completion of a significant acquisition. Boston Scientific Corporation has finalized its purchase of Axonics Modulation Technologies, a move that removes Axonics from public trading and consolidates its position within a larger entity. This strategic acquisition is poised to reshape the competitive dynamics in the market for sacral neuromodulation (SNM) therapies.

The transaction, valued at approximately $3.7 billion in equity value, saw Boston Scientific pay $71 per share in cash to Axonics shareholders. The primary objective for the acquiring company is a substantial expansion of its urology-focused portfolio. By integrating Axonics, Boston Scientific gains a suite of innovative implantable systems designed to treat bladder and bowel dysfunction. This portfolio includes both rechargeable and non-rechargeable devices, as well as solutions for female stress urinary incontinence.

From a financial perspective, Boston Scientific anticipates the deal will be largely neutral to its adjusted earnings per share throughout 2024 and 2025. The company projects that the transaction will begin to contribute positively to earnings starting in 2026, as operational synergies are realized.

Axonics’ Final Quarterly Report Shows Robust Growth

In its last independent earnings report for the third quarter of 2024, Axonics demonstrated strong operational performance. The company posted net sales of $116.2 million, representing a 25% year-over-year increase. Its gross margin also saw improvement, rising to 77.2% from 74.2% in the comparable period.

Despite this top-line growth, the quarter concluded with a minimal net loss of $21,000, a contrast to the $3.9 million net income recorded a year earlier. This result was primarily attributed to one-time costs totaling $8 million related to legal advisory services and transaction expenses for the acquisition. On an adjusted basis, however, EBITDA showed significant strength, climbing to $23.6 million from $14.0 million in the prior year.

Reshaping the Competitive Arena Against Medtronic

A key question following the acquisition is whether the combined entity can apply greater competitive pressure on market leader Medtronic. Even as a standalone company, Axonics had established itself as an aggressive competitor, engaging in years of intense patent litigation with the industry giant.

The integration into Boston Scientific provides Axonics’ technology with a significantly more powerful global commercial platform. The united company aims to capture greater market share in the pelvic health space by offering a broader range of solutions, seeking to alter the fundamental dynamics of the market over the long term.